Survival curves of 385 patients with MCL experiencing late POD divided according to second-line treatment. (A) PFS from time of second-line therapy (PFS-2) of BTKi vs R-BAC, R-B, or other approaches. (B) Overall survival from time of second-line therapy (OS-2) of BTKi vs R-BAC, R-B, or other approaches.